Last reviewed 2026-04-20 · How we verify

Tofacitinib Administration

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Upper respiratory tract infection
• Nasopharyngitis
• Bronchitis
• Urinary tract infection
• Hypertension
• Herpes zoster
• Rheumatoid arthritis
• Fall
• Back pain
• Arthralgia
• Diarrhoea
• Influenza

Key clinical trials

• Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease (PHASE2)
• The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea (NA)
• Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis (PHASE2, PHASE3)
• Observational Study To Assess The Effectiveness and Treatment Adherence Of Tofacitinib of Ulcerative Colitis In Clinical Practice In Sweden
• Therapies for Down Syndrome Regression Disorder (PHASE2)
• Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population
• A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase Syndrome (NA)
• A Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Tofacitinib Administration CI brief — competitive landscape report
• Tofacitinib Administration updates RSS · CI watch RSS
• Yale University portfolio CI